Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 1-12882 BOYD GAMING CORPORATION (Exact name of registrant as specified in its charter) Nevada 88-0242733 (State or other jurisdiction of incorporation o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 ______________________________________________ FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 1-2189 Abbott Laboratories An Illinois Corporation 36-0698440 100 Abbott Park Road Abbott Park, Illinois 600 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (State or other jurisdiction of incorporation or organization) Georgia 58-2567903 (I.R.S. Employer Identification No.) 3550 Lenox Road, Atlanta, Georgia 30326 (Address of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34674 Calix, Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | | 68-0438710 | | --- | --- | --- | | (State or O ...

Financial Performance - In 2025, the company achieved total revenue of $1.9 billion, primarily from sales of its COVID vaccines[22]. - The company expects to drive revenue growth in 2026 from long-term partnerships in the UK, Canada, and Australia, along with strong uptake of mNEXSPIKE in the U.S.[37]. Product Development and Clinical Trials - The company is advancing a pipeline of development candidates across oncology, rare disease, and infectious disease, with eight Phase 2 and Phase 3 clinical trials underway for intismeran[23]. - The company has a diverse development pipeline consisting of 35 therapeutic and vaccine programs, with 6 in late-stage development[58]. - The company continues to advance its early-stage pipeline, including oncology programs and multiple early-stage vaccine programs[38]. - The company anticipates pivotal trial data readouts in 2026 across its oncology, rare disease, and infectious disease portfolios, with plans to launch several new infectious disease products[37]. - The Phase 3 trial for mRNA-1018 is expected to begin in early 2026, following CEPI's investment[78]. - The Phase 3 trial of the trivalent vaccine candidate mRNA-1403 has enrolled about 38,000 participants, focusing on older adults who are at the highest risk of severe outcomes[95]. - The ongoing Phase 1/2 study of mRNA-4349 includes cohorts for first-line metastatic melanoma and first-line metastatic NSCLC[122]. - The registrational study for mRNA-3927 has reached target enrollment, and an infant dose-finding study is also ongoing[131]. Regulatory Approvals - The company has regulatory filings under review for its seasonal flu+COVID combination vaccine candidate (mRNA-1083) and expects a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026, for mRNA-1010[24]. - The FDA has approved the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years and all adults 65 years and older, with approvals received in 40 countries[64]. - The RSV vaccine (mRNA-1345 or mRESVIA) has been approved for adults 60 years and older, with recommendations for unvaccinated individuals aged 75 and older and high-risk individuals aged 50-74[66]. - The FDA accepted the BLA for mRNA-1010 for review, with a PDUFA goal date of August 5, 2026[71]. Manufacturing and Production - The company streamlined its production sites into a global manufacturing network, adding three facilities in the UK, Canada, and Australia to enhance local access to mRNA vaccines[26]. - The Marlborough biomanufacturing facility, completed in 2025, is designed for speed and scalability, and began shipping patient batches in September 2025[141]. - mRNA manufacturing facilities in the UK, Canada, and Australia were fully licensed in 2025, with multi-year commitments from local governments to purchase mRNA products[142]. - The company has invested significantly in manufacturing process science to produce mRNA medicines at scales ranging from micrograms to kilograms[52]. Strategic Collaborations - The company entered into a strategic collaboration with Recordati to advance its propionic acidemia therapeutic (mRNA-3927) through final stages of clinical development[25]. - Moderna's strategic alliance with Merck for personalized mRNA cancer vaccines includes an upfront payment of $200 million and a subsequent option exercise fee of $250 million[178][179]. - The collaboration with BARDA for the development of mRNA-1273, the original COVID vaccine, had a maximum award of approximately $1.8 billion, concluding on June 15, 2025[183]. - The company has entered into a collaboration with Recordati to advance investigational PA therapeutic (mRNA-3927) through clinical development and commercialization[182]. Intellectual Property - Moderna's intellectual property estate includes over 260 issued or allowed U.S. patents and more than 140 granted patents outside the U.S., with most patents not expiring until at least 2033[189]. - The projected expiration for U.S. patents covering the company's approved products, such as Spikevax and mNEXSPIKE, is 2041, while European patents are set to expire in 2036[198]. - The company maintains a multi-program effort to develop vaccines for potential future pandemics, targeting diseases such as Zika, dengue, HIV, and Nipah virus[206]. - The company's trademark portfolio includes at least 1,400 registrations and 180 pending applications across more than 55 jurisdictions[214]. Research and Innovation - The company has implemented AI-driven data analytics to optimize drug design, clinical trial operations, and manufacturing processes, enhancing efficiency and product quality[164][165][166]. - In early 2023, Moderna began a collaboration with OpenAI to integrate AI capabilities across various business functions, including legal, research, and manufacturing[167]. - The company is focused on expanding its modalities, which allows for rapid acceleration of programs based on learnings from earlier initiatives[56]. Economic Impact - Norovirus causes an estimated 685 million illnesses and 200,000 deaths annually, with a significant economic impact of approximately $60 billion per year globally[90]. - The economic burden of norovirus in the U.S. is estimated at $2 billion annually, with 20 million infections and 100,000 hospitalizations each year[90].

Exhibit 99.1 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, NJ, Feb. 20, 2026 – Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-36013 (American Homes 4 Rent) Commission File Number: 333-221878-02 (American Homes 4 Rent, L.P.) AMERICAN HOMES 4 R ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36786 RESTAURANT BRANDS INTERNATIONAL INC. (Exact name of Registrant as Specified in Its Charter) (State or Other ...

Consolidated Financial Statements For the years ended December 31, 2025 and 2024 (Expressed in thousands of United States dollars, unless otherwise stated) Consolidated Financial Statements For the years ended December 31, 2025 and 2024 | CONTENTS | | | --- | --- | | Management's Report | 3 | | Report of Independent Registered Public Accounting Firm – Consolidated Financial Statements | 4 | | Report of Independent Registered Public Accounting Firm – Internal Control over Financial Reporting | 6 | | Consolid ...